Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00KTV
|
|||
| Former ID |
DIB015318
|
|||
| Drug Name |
Salirasib
|
|||
| Synonyms |
162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Lung cancer [ICD-11: 2C25.0] | Phase 2 | [1], [2] | |
| Non-small-cell lung cancer [ICD-11: 2C25.Y] | Discontinued in Phase 2 | [2] | ||
| Pancreatic cancer [ICD-11: 2C10] | Discontinued in Phase 1/2 | [2] | ||
| Company |
Kadmon
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H30O2S
|
|||
| Canonical SMILES |
CC(=CCCC(=CCCC(=CCSC1=CC=CC=C1C(=O)O)C)C)C
|
|||
| InChI |
1S/C22H30O2S/c1-17(2)9-7-10-18(3)11-8-12-19(4)15-16-25-21-14-6-5-13-20(21)22(23)24/h5-6,9,11,13-15H,7-8,10,12,16H2,1-4H3,(H,23,24)/b18-11+,19-15+
|
|||
| InChIKey |
WUILNKCFCLNXOK-CFBAGHHKSA-N
|
|||
| CAS Number |
CAS 162520-00-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
520931, 11111197, 11691021, 12015205, 14925855, 17405080, 39463872, 47794599, 50070515, 50071153, 50106301, 50106302, 53777623, 53787349, 57363704, 75668216, 85231054, 91613201, 92303946, 96025678, 103191664, 103942479, 114016446, 124749775, 124880145, 135195440, 137010038, 142211576, 152258598, 160647433, 162263002, 178102901, 184823861, 198947135, 208265378, 223704994, 241377286, 250134226, 252158517, 252469227
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6281). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026972) | |||
| REF 3 | The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Methods Enzymol. 2008;439:467-89. | |||
| REF 4 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.